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Background: Overlapping relationships among migraine, epilepsy and major depression
have been identified in both cross-sectional case–control and prospective studies.
Clinical and neurophysiological examination of such comorbidity can illuminate shared
pathophysiology, and can have profound implications for diagnosis, prognosis, and
treatment.
Methods: During the period of January 2013 through July 2013, 87 cases were
diagnosed as epilepsy in remission according to International League Against Epilepsy
criteria. Migraine diagnosis was made according to the current International
Classification of Headache Disorders-II. EEG and brain MRI were done to confirm the
clinical diagnosis and physiological correlates.
Diagnosis of depression was based on detailed clinical and psychiatric assessment
according to the DSM IV using SCID 1 and Hamilton depression scale for assessment of
severity.
Results: A history of migraine was present in 19 (21.83%), while major depression
was present in 36(41.37%) of 87 epileptic patients. Comorbidity of migraine and
major depression was significantly evident in younger age group (p = 0.000) and
females (p = 0.01). Electroencephalography showed significantly more central and
temporal epileptic discharge in patients with comorbid migraine and frontotemporal
focal discharge in patients with major depression (p = 0.014).
Migraine onset was more likely to have occurred 1–3 years after epilepsy was
diagnosed in (36.84%) of comorbid cases.
Conclusion: It is important to address comorbidity in treating patients with epilepsy.
The diagnosis of atypical migraine symptoms can be quite difficult, in such cases EEG
may be useful. Some antiepileptic drugs (AEDs) like divalproex sodium (valproate) and
topiramate are effective in preventing migraine attacks, while others including
phenytoin, oxcarbazepine, vigabatrin and clonazepam, are not effective in migraine
prophylaxis. The antiepileptic drugs most closely associated with depression on
initiation of treatment are vigabatrin, phenobarbitone, and topiramate.Further research
on the nature and causes of the co-morbidity remains needed.
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The risk of migraine or depression is approximately twice in epilepsy compared to the
general population (Le et al., 2011). This well established clinical finding suggests that
the three disorders, epilepsy, migraine and depression might share many clinical fea-
tures and underlying pathophysiological mechanisms.
The Adult Psychiatric Morbidity Survey 2007 interviewed 7,403 individuals living in
England. Doctor-diagnosed epilepsy, asthma, diabetes, and migraine were ascertained
by self-report, and extensive diagnostic and screening interviews. The estimated life-
time prevalence of epilepsy in adults was 1.2% (95% confidence interval [CI] 1.0-1.5).
Almost one-third of the people with epilepsy had an International Classification of Dis-
eases, Tenth Revision (ICD-10) anxiety or depressive disorder (compared with one in
six people without epilepsy). Among these, social phobia and agoraphobia, generalized
anxiety disorder, depression, and measures of suicidality had strong associations with
epilepsy. These associations were consistently stronger than those in people with
asthma or diabetes, and similar to those in people reporting migraine or chronic head-
aches (Rai et al., 2012).
The complaint of headache may be confusing to the clinician. It may be part of
prodromal symptoms of epilepsy or more commonly postictal. Using established
diagnostic criteria may help to differentiate between comorbid migraine and
epilepsy-related headaches in classical cases but this is not the case in atypical
cases.
The concept of comorbidity could be examined on multiple levels.
First: patients could share the same genetic background as evident from family
history and linkage studies. Significant evidence of linkage was found between a
locus on 14q12-q23 and migraine suggestive of linkage in this region which was
also found for epilepsy with generalized tonic-clonic seizures. In addition, significant
evidence of linkage was found at a locus on 12q24.2-q24.3 for migraine alone and
for the combined phenotype of migraine and epilepsy. These data suggest the oc-
currence of common susceptibility loci for epilepsy and migraine on chromosomes
14q12-q23 and 12q24.2-q24.3, implicating a shared genetic etiology for these two
disorders (Polvi et al., 2012).
However, the presence of related genes is not enough by itself to explain comorbidity
as many epigenetic factors can affect gene expression.
Second: across the life span, disease development may affect different neuronal cir-
cuits in different patients giving way to unique presentations in every patient in terms
of disease prognosis and associated comorbidity. Migraine attacks could be epilepto-
genic and over time lead to the development of epilepsy, or, alternatively, recurrent sei-
zures could lead to the development of migraine.
Depression and epilepsy may be linked temporally to seizures, but more com-
monly depression tends to occur inter-ictally. The bidirectional relationship be-
tween epilepsy and depression is not specific to Temporal Lobe Epilepsy (TLE) as
indicated by failure to demonstrate alterations of serotonin binding properties in
patients with epilepsy with or without symptoms of depression (Liik et al., 2013).
There is strong evidence that the relationships among these comorbid disorders
are bidirectional. Depression and suicidality are more prevalent among epilepsy
patients, they have been shown to precede the onset of seizures and to occur
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2010).
The idea that migraine may lead to epilepsy was once proposed as an explan-
ation for the comorbidity (Le et al., 2011; Polvi et al., 2012). Epidemiological data
indicate that this explanation is unlikely (Silberstein et al., 2008). If migraine
caused epilepsy, for example by inducing brain injury, the incidence of epilepsy
should be increased in individuals with preexisting migraine. The epidemiological
results demonstrate that there is excess risk of epilepsy both before and after the
onset of migraine, leading to the rejection of the unidirectional causality hypoth-
esis. The simple genetic risk hypothesis was discarded and instead a theory was
proposed that a state of brain hyperexcitability, which can be produced either by
genetic factors or can be acquired (such as in a head injury), increases the risk of
both migraine and epilepsy, thus leading to the comorbid association (Ottman &
Lipton 1996).
In each of the previous studies, one predictive factor for this comorbidity was exam-
ined and their results are still confusing with many study limitations including small
sample size, diagnosis, comorbidity, and age of onset.
The bidirectional relationship and an evidence-based framework can guide the treat-
ment of mood disorders that are comorbid with medical illness. Recent review on the
links between mood disorders and common medical conditions, evaluated the efficacy
and safety of pharmacologic and psychosocial treatments. The medical disorders most
commonly encountered in adult populations with depression were cardiovascular dis-
ease, cerebrovascular disease, cancer, human immunodeficiency virus, hepatitis C virus,
migraine, multiple sclerosis, epilepsy, and osteoporosis. Emerging evidence suggests
that depression comorbid with several medical disorders is treatable and failure to treat
depression in medically ill patients may have a negative effect on medical outcomes
(Ramasubbu et al., 2012).
Defining the comorbidity between epilepsy, migraine and depression is important to
set suitable management plan avoiding some antiepileptics that can worsen other co-
morbidities and hence the patient’s whole prognosis.Objectives
The objectives of the current study were to examine the demographics (age of onset, sex),
clinical (type of epilepsy) and neurophysiological (electroencephalographic changes)
factors that help to predict the comorbidity of epilepsy, migraine and depression and
therapeutic implications.Methods
Study setting
This study is a cross sectional observational study conducted during the period of January
2013 through July 2013.
Epileptic patients were recruited from neurology out and inpatient departments from
BenySweif and Ain Shams University hospitals after approval of the study protocol
from the concerned ethical committee in both medical departments. This work has
been carried out in accordance with code of ethics of the Word Medical Association
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the study.
Participants
Of a total of 120 patients, as calculated by Graphpad Stat Mate, diagnosed as epi-
leptics in remission according to International League Against Epilepsy (ILAE) cri-
teria, 87 patients completed the study investigations, Electroencephalography (EEG)
and Brain Magnetic Resonance Imaging (MRI). Fourty eight males and 39 females
were included in the study. Their ages ranged from 18–45 years. Those with history
of head trauma, drug abuse and serious medical or neuropsychiatric disorders were
excluded.
All 87 subjects with epilepsy included in the study were assessed using semi
structured neuropsychiatric interview done by neuropsychiatry specialist containing
demographic data (age, sex, level of education, occupation, marital status, residence),
past and family history of medical, psychiatric disorders and drugs, full history of
epilepsy (onset, type, aura, frequency and drug response), associated migraine and
depression (onset, number of previous episodes, presenting symptoms, suicidal
thoughts or attempts, hospitalization and treatment). Antiepileptic drugs (AEDs) in-
cluded carbamaezepine, lamotirgine, levitracetam and sodium valproate; Antimi-
graine drugs included triptans (Imigran) and ergot alkaloids (dihydroergotamine and
methysergide), Gabapentin, pregabalin and selective serotonin reuptake inhibitors
(SSRIs) were used for emotional disturbances (mainly ecitalopram and sertraline).
Full medical and neuropsychiatric examination was done. Clinical diagnosis of mi-
graine was obtained by neurological history and examination according to the
current International Classification of Headache Disorders-II and diagnosis of de-
pression according to the DSM IV using SCID 1 and Hamilton Depression Rating
Scale (HDRS) for assessment of severity. All subjects were divided into 3 groups for
comparing demographic, clinical and EEG variables, according to clinical and diag-
nostic criteria. Group 1was comprised of patients with epilepsy without comorbid-
ity, group 2 included epileptic patients with comorbid migraine and group 3
epileptic patients with comorbid depression.
Statistical analysis
Collected data were analysed using statistical package of social sciences SPSS ver-
sion 17. Qualitative variables were described in number and percentages. Quanti-
tative variables were described in mean and standard deviations. Pearson Chi
Square test was used to detect presence or absence of significant association be-
tween two categorical variables. Independent sample t-test was used to compare
between means of different groups of patients. Analysis of Variance (ANOVA)
tests were used when comparing quantitative data between more than two groups.
P value was used to indicate the level of significance (p < 0.05 is considered
significant, p < 0.01 is considered highly significant).
Results
Subjects who completed the study (N = 87) diagnosed as epileptics in remission
according to International League Against Epilepsy (ILAE) criteria, had an age
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cluded patients 47 (54.02%) had generalized epileptic fits, while 24 (27.58%) had
temporal lobe fits and 16 (18.39%) had extra-temporal focal fits. No evident
changes were observed in Brain MRIs. The onset of epilepsy ranged from 12–18
years of age (as shown in Table 1).
Nineteen patients (21.83%) 7 males/12females met criteria of diagnosis of comorbid
migraine, while 36 (41.37%) met criteria of diagnosis of comorbid depression 11males/
25 females with severity of HDRS ranging from 18–25 (M + SD 21 + 3.3).
There were significant differences in gender between the three groups (epileptic
patients without comorbidity, those with comorbid migraine, and those with
comorbid depression), with comorbidity more likely to occur in females (p = 0.01).
In comparison between patients with and without comorbid migraine and depression,
the comorbid group had significantly younger age of onset (Mean + SD = 34 + 6.1,
23 + 2.4, 22 + 1.6, respectively (p = 0.000). Migraine was significantly encountered
in epilepsy patients with epileptic discharge in the central and temporal regions
and depression in frontotemporal epileptic changes (p = 0.014) (as shown in
Tables 2 and 3).
Three patients (15.7%) described light flashes both as epileptic and migraine
visual aura. Migraine onset followed epilepsy diagnosis in 12 patients (63.16%), and
in 7 (36.84%) before epilepsy diagnosis, while depression was diagnosed 2–5 years
before epilepsy in 28 patients (77.7%). This difference didn’t reach statistical signifi-













Primary level 16 18.39%
Secondary technical level 63 72.41%
Epilepsy type
Generalized epileptic fits 47 54.02%
Temporal lobe fits 24 27.58%
Extratemporal focal fits 16 18.39%
Onset of epilepsy Range 21.83%
12-18 years M + SD 13.2 + 1.1
Table 2 Demographic and clinical data for 3 groups of epileptic patients









No (%) 32 (36.78%) 19 (21.83%) 36 (41.37) 0.004
Age range Age Range Age range Age Range 0.000
Mean + SD 21-42 Mean + SD
34 + 6.1
18- 32 Mean + SD
23 + 2.4
20-28 Mean + SD
22 + 1.6
SEX SEX SEX SEX 0.01
Male :Female Male :Female Male :Female Male :Female
30 : 2 7 : 12 11 :25
Onset of
migraine
after epilepsy diagnosis after epilepsy diagnosis 0.63
12(63.16%) 28(77.7%)
before epilepsy diagnosis before epilepsy diagnosis
7 (36.84%) 8 (22.22%)
Aura with
migraine







HDRS (21 + 3.3)





Antimigraine drugs selective serotonin reuptake
inhibitors (SSRIs) ecitalopram






There was significant difference among group in younger age of onset (p = 0.000) and female gender (p = 0.01) between
patient groups with and without comorbid migraine and depression.
Table 3 Electroencephalographic changes in 3 groups of patients
GROUP 1 GROUP 2 GROUP 3 P value
EEG Changes in epileptic
patients without comorbidity
EEG Changes in epileptic
patients with comorbid migraine
EEG changes in patients with
comorbid depression
0.014
N 32 (36.78%) N 19 (21.83%) N 36(41.37%)
Focal discharge 11 Focal discharge 15 Focal discharge 29
Frontal 4 Frontal 3 Frontal 11
Central 4 Central 7 Central 3
Temporal 3 Temporal 5 Temporal 15
Paroxysmal discharge 21 Paroxysmal discharge 6 Paroxysmal discharge 9
Migraine was more common in epileptic patients with EEG discharge activity in central and temporal regions, while
depression was more common with frontotemporal changes.
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In this study, history of migraine was present in 19 patients (21.83 %), while major de-
pression was present in 36 patients (41.37%) out of 87 patients diagnosed as epileptics
in remission according to International League Against Epilepsy (ILAE) criteria. Co-
morbidity of migraine and major depression was significantly evident in younger age
group (p = 0.000) and females (p = 0.01). Electroencephalography showed significantly
more central and temporal epileptic discharge in patients with comorbid migraine and
frontotemporal focal discharge in patients with major depression (p = 0.014).
Migraine onset was more likely to have occurred 1–3 years after epilepsy was diag-
nosed in (36.84%) of comorbid cases, while depression was diagnosed 2–5 year after
epilepsy in (77.7%) of depressed patients.
The prevalence of migraine in populations of individuals with epilepsy is estimated as
8–24% (Toldo et al., 2010), so that the risk of migraine is approximately twice that in
the normal population (Ottman & Lipton, 1994).
This coincides with our finding that 21.83% of our patients with epilepsy have comor-
bid migraine. The diagnosis of migraine in our study was significantly correlated with
younger age and female gender. Thus comorbidity of migraine was more common in
women which could be explained by hormonal effect (Le et al., 2011).
The onset of epilepsy proceeded the diagnosis of migraine 1–3 years in 12 patients
(63.16%). The same results were reported in other studies that found that migraine had
more co-morbidities in females than males (Le et al., 2011).
Migraine attacks could be epileptogenic and over time lead to the development of
epilepsy, or, alternatively, recurrent seizures could lead to the development of migraine.
Across life span the disease development affects different neuronal circuits that are not
the same in all patients giving way to unique presentation in every patient in terms of
disease prognosis and associated comorbidity.
Estimates of the prevalence of depression in epilepsy vary. Epidemiological studies
suggest A prevalence of 20–30% in those with recurrent seizures but only 6–9% in
those whose epilepsy is in remission (Edeh & Toone, 1987). These findings have been
replicated by another community health survey (Tellez-Zenteno et al., 2007).
The above studies show that the prevalence rates of depression are much higher in
epilepsy than those reported in the general population. In the present study major de-
pression were encountered in 36 patients (41.37%). Mean scores for HDRS (21 + 3.3)
ranged from moderate to severe cases particularly in patients who showed more fronto-
temporal epileptic changes.
Depressed mood, agitation, retardation, and absence of insight were the depressive
symptoms more commonly seen among epilepsy patients as compared to those with
migraine. People with temporal lobe epilepsy appear to be at greater risk than those
with idiopathic generalized epilepsy, suggesting that it is not just the presence of sei-
zures or social consequences of a diagnosis of epilepsy. Depression in a first degree
relative has also been identified as an independent risk factor pointing to a genetic pre-
disposition. Paradoxically, depression can follow remission of epilepsy either after epi-
lepsy surgery or the initiation of an effective antiepileptic drug (Krishnamoorthy, 2004).
In the Epilepsy Family Study, among probands with epilepsy who were classified as
having migraine on the basis of their self-reported symptoms, only 44% reported
physician-diagnosed migraine. In the general population, 29% of men and 40% of
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have occurred after epilepsy was diagnosed (p = 0.0002), but was not more prevalent in
those with intractable epilepsy (Silberstein & Lipton, 2002).
This study shows that 56% of cases missed diagnosis by their doctors, either because
they are not aware of the prevalence of comorbidity between epilepsy and migraine or
they attributed the complain of headache to epilepsy.
In typical patients, the clinical history usually allows the separation of migraine
and epilepsy. The diagnosis of atypical migraine symptoms can be quite difficult.
However, a number of epileptic and nonepileptic syndromes may mimic migraine.
In more complex cases, EEG and video-EEG monitoring are useful. Because mi-
graine and epilepsy are associated, clinicians should be sensitive to the issue of
concomitant diagnoses. Some patients with epilepsy and migraine may not report
their headaches because the headaches are being effectively treated with an antiepi-
leptic drug without a diagnosis of migraine. Because of its greater prevalence, mi-
graine is common in people with epilepsy, whereas epilepsy is rare in migraineurs.
The diagnosis and treatment of each disorder must take into account the potential
presence of the other.
Cortical depolarization, is believed to underlie migraine. The initial event preced-
ing onset of migraine is cellular hyperexcitability associated with localized epilepti-
form discharges. Glutamate is a critical mediator of the hyperexcitability in both
focal seizures and migraine. Some antiepileptic drugs prevent the occurrence of mi-
graine attacks, supporting the view that neuronal hyperexcitability is an initiating
event. Strong support for a shared genetic basis comes from familial hemiplegic mi-
graine (FHM), an autosomal dominant syndrome characterized by severe migraine,
FHS arises as a result of mutations in genes for the membrane ion transport pro-
teins CACNA1A (P/Q-type voltage-gated calcium channel), ATP1A2 (Na+-K+
ATPase), and SCN1A (voltage-gated sodium channel). Allelic mutations in all three
genes also cause generalized and in some cases focal epilepsy (Haan et al., 2008,
Haut et al., 2006).
Migraine-like features sometimes characterize the headache that follows epileptic
seizure (postictal headache, PIH). Forty percent of epileptic patients had PIH and 26%
of these patients had migraine-like PIH. Migraine-like PIH occurred significantly more
often in temporal lobe epilepsies and occipital lobe epilepsies. The incidence of interic-
tal migraine headache was significantly higher in patients with migraine-like PIH. These
results suggest that migraine-like PIH is related to particular regions of epileptogenic
focus and that susceptibility to migraine headache predisposes to migraine-like PIH
(Ito et al., 2004).
Genetically determined dysfunction of ion channels seems to point to a common under-
lying mechanism for both paroxysmal disorders. It is likely that the development of specific
drugs aimed at restoring ion-channel function and/or related cellular signalling pathways
might benefit patients with epilepsy as well as those with migraine (Haan et al., 2008).
Current knowledge of the psychopharmacology of (AEDs) suggests that it is possible
to distinguish between drugs with potential positive effects, and others with detrimental
effects.
There is extensive evidence from randomized controlled clinical trials that the
(AEDs) divalproex sodium (valproate) and topiramate are effective in preventing
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also be effective in migraine therapy (D’Amico, 2010, Calandre et al., 2010). One other
AED that has been reported to be useful in migraine prophylaxis is levetiracetam
(Drake et al., 2001).
AEDs reduce neuronal hyperexcitability by various mechanisms (Macdonald &
Rogwski, 2008). Some AEDs, including phenytoin, oxcarbazepine, vigabatrin and clo-
nazepam, are not effective in migraine prophylaxis. However, for both epilepsy and mi-
graine, a proportion of patients are pharmacoresistant (around 30% in both conditions)
(Bermejo & Dorado, 2009; Villani et al., 2011).
AEDs have a high psychotropic potential. In fact, this class of compounds is exten-
sively used in psychiatric practice as mood stabilizers (Melvin et al., 2008), antianxiety
agents (Vazquez & Devinsky, 2003), or in withdrawal syndromes (Zullino et al., 2004)
beyond their antiseizure effect, but possibly dealing with a sub-clinical hyperexcitability
(Boutros et al., 2013).
The AEDs most associated with the occurrence of depressive symptoms in patients
with epilepsy seem to be those which act at the benzodiazepine—GABA receptor com-
plex, and include barbiturates, topiramate and vigabatrin (Mula et al., 2008).
Data on tiagabine, levetiracetam and felbamate seem to be associated with an inter-
mediate risk and an incidence of inducing depression of about 3% has been reported
(Mulla and Shmitz, 2009).
The other AEDs show a low incidence of depression (less than 1%). The antiepileptic
drugs most closely associated with acute depression on initiation of treatment are viga-
batrin, phenobarbitone, and topiramate. Depression with topiramate may be linked to
abrupt cessation of seizures or drug toxicity (Mulla and Shmitz, 2009).
Evidence that antidepressants are associated with seizures comes largely from pa-
tients who have taken overdoses. That tricyclic overdose carries a high risk of pro-
voked seizures is well documented, but the risk with low dose is probably minimal.
Nevertheless, because of the risk of overdose in patients with depression tricyclic
agents are best avoided and use of the selective serotonin reuptake inhibitors
(SSRIs) or serotonin–norepinephrine reuptake inhibitors (SNRIs) are to be preferred
(Krishnamoorthy, 2004).
Evidence to support this is hard to find, but there has been one open label study of
sertraline in epilepsy that showed worsening of seizures in only 6% of patients. Given
the morbidity and mortality associated with untreated depression, this risk is rela-
tively low. Pharmacokinetic drug interactions between SSRIs and AED are rare, with
the exception of inhibition of carbamazepine and phenytoin metabolism by fluvox-
amine. Care needs to be taken with the combination of either carbamazepine or
oxcarbazepine and SSRIs because of the tendency for both to cause hyponatraemia
(Kanner et al., 2000).
Study Limitations
The most important limitation of this study is the small number of subjects stud-
ied and being cross sectional. It would be helpful in further research to conduct
prospective follow up study on larger sample to predict comorbidity and prognosis
overtime in relation to type of epilepsy, degree of improvement and type of drug
used.
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Epilepsy, migraine and depression are comorbid conditions. This is likely due to shared
genetic or environmental factors. In typical patients, the clinical history usually allows
the separation of migraine and epilepsy. The diagnosis of atypical migraine symptoms
can be quite difficult in such cases EEG may be useful. AEDs may have negative effects
on mood and behaviour. Current knowledge on psychopharmacology of AEDs suggests
that it is possible to distinguish between drugs with potential positive effects on mood,
and others with detrimental effects.Competing interests
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